Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.19
-4.09 (-1.78%)
AAPL  278.28
+0.25 (0.09%)
AMD  210.78
-10.65 (-4.81%)
BAC  55.14
+0.58 (1.06%)
GOOG  310.52
-3.18 (-1.01%)
META  644.23
-8.48 (-1.30%)
MSFT  478.53
-4.94 (-1.02%)
NVDA  175.02
-5.91 (-3.27%)
ORCL  189.97
-8.88 (-4.47%)
TSLA  458.96
+12.07 (2.70%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.